Protective Effects of IMOD and Cimetidine Against Radiation-induced Cellular Damage

Overview

Journal J Biomed Phys Eng

Publisher Shiraz University of Medical Sciences

Specialty Biomedical Engineering

Date 2018 May 8

PMID 29732348

Citations 2

Authors

S Rahgoshai

M Mohammadi

S Refahi

M Oladghaffari

S M R Aghamiri

Affiliations

Soon will be listed here.

Abstract

Radiation damage is to a large extent caused by overproduction of reactive oxygen species (ROS). Radioprotectors are agents or substances that reduce the effects of radiation in healthy normal tissues while maintaining the sensitivity to radiation damage in tumor cells. Radioprotectors are agents or substances that reduce the effects of radiation in healthy normal tissues while maintaining the sensitivity to radiation damage in tumor cells Cimetidine was found more effective when used in vivo; this effect might be due to the augmentation of the presence of Sulphur atom in the compound which is ýimportant for their scavenging activity. Recently, a new herbal-based medicine with immunomodulatory capacities, Setarud (IMOD), was introduced as an additional therapy in various inflammatory diseases and HIV infection. IMOD is a mixture of herbal extracts enriched with selenium. Selenium confers protection by inducing or activating cellular free-radical scavenging systems and by enhancing peroxide breakdown. This article suggests that nontoxic amount of IMOD and cimetidine have radioprotective properties and could reduce cytotoxic effects of radiation.

Citing Articles

Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial.

Rostami M, Yelghi O, Moghaddam Z, Zeraatchi A, Rezaeejam H, Sadeghi A Radiat Oncol. 2023; 18(1):83.

PMID: 37210511 PMC: 10199581. DOI: 10.1186/s13014-023-02281-w.

Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies.

Allegra A, Mannino F, Innao V, Musolino C, Allegra A Antioxidants (Basel). 2020; 9(11).

PMID: 33198328 PMC: 7696711. DOI: 10.3390/antiox9111116.

References

Nair C, Salvi V, Kagiya T, Rajagopalan R . Relevance of radioprotectors in radiotherapy: studies with tocopherol monoglucoside. J Environ Pathol Toxicol Oncol. 2004; 23(2):153-60. DOI: 10.1615/jenvpathtoxoncol.v23.i2.80. View

Eroglu C, Unal D, Cetin A, Orhan O, Sivgin S, Ozturk A . Effect of serum selenium levels on radiotherapy-related toxicity in patients undergoing radiotherapy for head and neck cancer. Anticancer Res. 2012; 32(8):3587-90. View

Manea A, Fortuno A, Martin-Ventura J . Oxidative stress in cardiovascular pathologies: genetics, cellular, and molecular mechanisms and future antioxidant therapies. Oxid Med Cell Longev. 2013; 2012:373450. PMC: 3549365. DOI: 10.1155/2012/373450. View

MARSHALL M, Conley D, Hollingsworth P, Brown S, Thompson J . Effects of coumarin (1,2-benzopyrone) on lymphocyte, natural killer cell, and monocyte functions in vitro. J Biol Response Mod. 1989; 8(1):70-85. View

Mirzaee S, Drewniak A, Sarrami-Forooshani R, Kaptein T, Gharibdoost F, Geijtenbeek T . Herbal medicine IMOD suppresses LPS-induced production of proinflammatory cytokines in human dendritic cells. Front Pharmacol. 2015; 6:64. PMC: 4375992. DOI: 10.3389/fphar.2015.00064. View

Mozdarani H, Gharbali A . Radioprotective effects of cimetidine in mouse bone marrow cells exposed to gamma-rays as assayed by the micronucleus test. Int J Radiat Biol. 1993; 64(2):189-94. DOI: 10.1080/09553009314551291. View

Soref C, Hacker T, Fahl W . A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses. Int J Radiat Oncol Biol Phys. 2012; 82(5):e701-7. DOI: 10.1016/j.ijrobp.2011.11.038. View

C Jagetia G . Radioprotective Potential of Plants and Herbs against the Effects of Ionizing Radiation. J Clin Biochem Nutr. 2008; 40(2):74-81. PMC: 2127223. DOI: 10.3164/jcbn.40.74. View

Lapenna D, de Gioia S, Mezzetti A, Grossi L, Festi D, Marzio L . H2-receptor antagonists are scavengers of oxygen radicals. Eur J Clin Invest. 1994; 24(7):476-81. DOI: 10.1111/j.1365-2362.1994.tb02378.x. View

10.

Momm F, Bechtold C, Fischer K, Tsekos A, Henke M . [Alteration of radiation-induced hematotoxicity by amifostine (ethyol)]. Strahlenther Onkol. 1999; 175 Suppl 4:2-5. View

11.

Weiss J, Hoover R, Kumar K . Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721. Free Radic Res Commun. 1987; 3(1-5):33-8. DOI: 10.3109/10715768709069767. View

12.

Cicek E, Yildiz M, Delibas N, Bahceli S . The effects of 201Tl myocardial perfusion scintigraphy studies on oxidative damage in patients. West Indian Med J. 2009; 58(1):50-3. View

13.

Islamian J, Mohammadi M, Baradaran B . Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview. Cancer Biol Med. 2014; 11(2):78-85. PMC: 4069799. DOI: 10.7497/j.issn.2095-3941.2014.02.002. View

14.

BADIELLO R, Fielden E . Pulse radiolysis of selenium-containing radioprotectors. I. Selenourea. Int J Radiat Biol Relat Stud Phys Chem Med. 1970; 17(1):1-14. DOI: 10.1080/09553007014550011. View

15.

Xu P, Zhang W, Cai X, Lu D, He X, Qiu P . Flavonoids of Rosa roxburghii Tratt act as radioprotectors. Asian Pac J Cancer Prev. 2014; 15(19):8171-5. DOI: 10.7314/apjcp.2014.15.19.8171. View

16.

Ozturk P, Arican O, Belge Kurutas E, Karakas T, Kabakci B . Oxidative stress in patients with scalp seborrheic dermatitis. Acta Dermatovenerol Croat. 2013; 21(2):80-5. View

17.

Patchen M, MacVittie T, Weiss J . Combined modality radioprotection: the use of glucan and selenium with WR-2721. Int J Radiat Oncol Biol Phys. 1990; 18(5):1069-75. DOI: 10.1016/0360-3016(90)90442-m. View

18.

Kupper F, Kloareg B, Guern J, Potin P . Oligoguluronates elicit an oxidative burst in the brown algal kelp Laminaria digitata. Plant Physiol. 2001; 125(1):278-91. PMC: 61009. DOI: 10.1104/pp.125.1.278. View

19.

Brizel D, Wasserman T, Henke M, Strnad V, Rudat V, Monnier A . Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000; 18(19):3339-45. DOI: 10.1200/JCO.2000.18.19.3339. View

20.

Farhoudi M, Najafi-Nesheli M, Hashemilar M, Mahmoodpoor A, Sharifipour E, Baradaran B . Effect of IMOD™ on the inflammatory process after acute ischemic stroke: a randomized clinical trial. Daru. 2013; 21(1):26. PMC: 3620936. DOI: 10.1186/2008-2231-21-26. View